Iris Löw-Friedrich
Chief Executive Officer presso ZOGENIX, INC.
Profilo
La dottoressa Iris Lw-Friedrich è vicepresidente del consiglio di sorveglianza di Evotec SE, Chief Medical Officer & Executive Vice President di UCB SA e professore alla Johann Wolfgang Goethe-Universitt Frankfurt am Main. Fa parte del Consiglio di amministrazione di Fresenius SE & Co. KGaA e Evotec SE. La dottoressa Lw-Friedrich è stata precedentemente impiegata come presidente di Transcelerate Biopharma, Inc., membro del consiglio di sorveglianza di Heidelberg Pharma AG, direttore di ricerca e sviluppo di UCB Pharma GmbH, vicepresidente dei progetti globali di BASF Pharma, vicepresidente dei progetti globali di BASF AG, vicepresidente dello sviluppo clinico di Hoechst AG, responsabile della gestione clinica globale e vicepresidente di Aventis Pharma AG e vicepresidente dello sviluppo clinico di Hoechst Marion Roussel, Inc. Ha ricevuto il suo dottorato dalla Johann Wolfgang Goethe-Universitt Frankfurt am Main.
Posizioni attive di Iris Löw-Friedrich
Società | Posizione | Inizio |
---|---|---|
UCB | Chief Tech/Sci/R&D Officer | 01/03/2008 |
EVOTEC SE | Chairman | 15/06/2021 |
FRESENIUS SE & CO. KGAA | Director/Board Member | 13/05/2016 |
ZOGENIX, INC. | Chief Executive Officer | - |
Johann Wolfgang Goethe-Universität Frankfurt am Main | Corporate Officer/Principal | 01/01/2000 |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | Director/Board Member | 01/04/2019 |
Precedenti posizioni note di Iris Löw-Friedrich
Società | Posizione | Fine |
---|---|---|
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Chairman | 01/09/2017 |
UCB Pharma GmbH
UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany. | Chief Tech/Sci/R&D Officer | 01/01/2009 |
BASF SE | Corporate Officer/Principal | 01/01/2001 |
░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formazione di Iris Löw-Friedrich
Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 5 |
---|---|
FRESENIUS SE & CO. KGAA | Health Technology |
BASF SE | Process Industries |
UCB | Health Technology |
EVOTEC SE | Health Technology |
HEIDELBERG PHARMA AG | Health Technology |
Aziende private | 8 |
---|---|
Hoechst AG
Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
UCB Pharma GmbH
UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany. | Health Technology |
Zogenix, Inc.
Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Aventis Pharma AG | |
Hoechst Marion Roussel, Inc. | |
BASF Pharma | |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | Commercial Services |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Health Technology |
- Borsa valori
- Insiders
- Iris Löw-Friedrich